IMAAVY maintains disease control through two years in adolescents with generalised myasthenia gravis
Posted on October 4, 2026
Johnson & Johnson has reported new long term findings for IMAAVY, also known as nipocalimab aahu, showing sustained disease control through two years in adolescents with generalised myasthenia gravis.
The findings are among 15 new IMAAVY abstracts being presented at the 2026 Myasthenia Gravis Foundation of America Scientific Session and American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting.
Two year results from the Phase II and III Vibrance MG long term extension study showed that adolescents with anti acetylcholine receptor antibody positive generalised myasthenia gravis maintained improvements in daily functioning and muscle strength while receiving IMAAVY.
Reductions in corticosteroid use were also observed during extended treatment.
Among adolescents with available data at week 108, the mean change from baseline in Myasthenia Gravis Activities of Daily Living score was minus 2.88 points.
The mean improvement in Quantitative Myasthenia Gravis score reached minus 8.25 points at the same time point.
Johnson & Johnson said these improvements were consistent with results observed at weeks 4 and 24 and were maintained across the intervening assessments through two years.
Corticosteroid use also declined during the study.
Of six adolescents who were receiving corticosteroids when they entered the trial, three reduced their dose and one discontinued corticosteroid treatment after two years on IMAAVY.
No new safety signals were identified during up to two years of treatment.
The safety profile observed in adolescents was similar to that previously reported in adults.
Jonathan Strober, MD, Director of the Pediatric Neuromuscular Program and Neuromuscular Clinic sponsored by the Muscular Dystrophy Association, said the unpredictable muscle weakness associated with generalised myasthenia gravis can interfere with school, social activities and independence among adolescents.
He said the two year Vibrance MG findings provide encouraging evidence of sustained improvements in daily function and muscle strength alongside reduced corticosteroid use.
Johnson & Johnson also presented findings from a retrospective survey examining treatment decisions among healthcare professionals caring for adults with anti acetylcholine receptor or anti MuSK antibody positive generalised myasthenia gravis.
Fluctuating symptom control was the most frequently reported reason for discontinuing a previous advanced therapy, cited for 54.6% of patients.
Among 97 patients who transitioned from another advanced treatment to IMAAVY, healthcare professionals most commonly cited a preference for a consistent treatment schedule and the expectation of improved efficacy.
A consistent treatment schedule was identified as a reason for starting IMAAVY in 62.9% of cases, while 56.7% cited the prospect of improved efficacy.
Following the transition, healthcare professionals reported that 73.2% of patients were much improved or very much improved.
Among patients receiving prednisone, 76.4% reduced their dose and 5.5% discontinued the medicine.
David M. Lee, MD, PhD, Global Immunology Therapeutic Area Head at Johnson & Johnson, said fluctuating symptoms remain an important unmet need in generalised myasthenia gravis and can influence decisions to switch treatments.
He said evidence across both adolescents and adults continues to support the potential of IMAAVY to provide sustained disease control while reducing reliance on corticosteroids.
IMAAVY is an immunoselective treatment designed to substantially reduce pathogenic immunoglobulin G while preserving B cell function.
The medicine is currently the only FcRn blocker approved by both the U.S. Food and Drug Administration and European Medicines Agency for paediatric patients aged 12 years and older with anti acetylcholine receptor or anti MuSK antibody positive generalised myasthenia gravis.
Related Topics and Keywords
AANEM 2026, Biopharma, clinical trials, corticosteroids, FcRn blocker, generalised myasthenia gravis, gMG, IMAAVY, Immunology, Johnson and Johnson, MGFA 2026, myasthenia gravis, neurology, nipocalimab, pharma news, Phase II, phase III, Vibrance MG
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
